Organon & Co. OGN 深 沪
等待开盘 06-25 09:30:00 美东时间
13.455
+0.005
+0.04%
华盛通- 最 高13.47
- 今 开13.45
- 成交量 106.96万股
- 最 低 13.4407
- 昨 收 13.45
- 总市值 35.33亿
- 52周最高 13.49
- 市盈率 静 18.76
- 换手率 0.00%
- 52周最低 5.67
- 委 比 -24.13%
- 总股本 2.63亿
- 历史最高 36.015
- 量 比 0.78
- 振 幅 0.22%
- 历史最低 5.67
- 每 手 1
- 风险率 2.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多复宏汉霖两款地舒单抗产品在加拿大商业化上市，携手Organon提升区域骨健康治疗...
内容来源：复宏汉霖 中国上海和加拿大魁北克省柯克兰市，2025年6月23日——复宏汉霖与Organon加拿大今日宣布，地舒单抗注射液（60 mg/mL）BI...
06-24 19:25
复星医药子公司复宏汉霖地舒单抗BILDYOS与TUZEMTY在加拿大商业化上市，提升骨健康治疗可及性
中国上海和加拿大魁北克省柯克兰市，2025年6月23日——复星医药子公司复宏汉霖（2696.HK）与Organon加拿大今日宣布，地舒单抗注射液（60 mg/...
06-24 17:35
Organon and Henlius launch Prolia and Xgeva biosimilars in Canada
Organon Canada (OGN) and Shanghai Henlius Biotech on Tuesday announced the Canadian launch of Bildyos (denosumab injection) and Tuzemty (denosumab injection), biosimilars to Prolia and Xgeva, respecti...
06-23 18:28
Organon And Samsung Bioepis Expand Their Development And Commercialization Agreement To Provide OGN With Commercialization Rights In Canada To PYZCHIVA, Samsung Bioepis's Biosimilar Referencing STELARA
PYZCHIVA® is indicated for the treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn's disease who have had an inadequate response, loss of response to, or ...
06-18 18:08
Organon, Samsung Bioepis expand Canada commercialization pact for ustekinumab biosimilar PYZCHIVA
Organon, Samsung Bioepis expand Canada commercialization pact for ustekinumab biosimilar PYZCHIVA Organon expanded its partnership with Samsung Bioepis to secure exclusive commercialization rights in Canada for PYZCHIVA, a Stelara-referencing ustekinumab biosimilar. Samsung Bioepis retains responsib
06-18 18:00
Organon Sets July Vote on $14‑per‑Share Sun Pharma Takeover
New activity is brewing for Organon ( ($OGN) ). The company has submitted a For...
06-17 18:47
Organon Shareholders Approve Board, Pay and Incentive Plan
Organon ( ($OGN) ) has provided an announcement. At its 2026 annual meeting hel...
06-12 05:43
Organon's Supplemental Biologics License Application Gets FDA Approval For TOFIDENCE To Treat Chimeric Antigen Receptor T Cell-Induced Severe Or Life-Threatening Cytokine Release Syndrome
Organon (NYSE:OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to includ...
06-10 19:33
Organon says FDA approves expanded TOFIDENCE use in CAR-T cytokine release syndrome
Organon says FDA approves expanded TOFIDENCE use in CAR-T cytokine release syndrome FDA cleared expanded US uses for Organon’s TOFIDENCE (tocilizumab-bavi), adding CAR-T-induced severe or life-threatening cytokine release syndrome. The label also now covers hospitalized COVID-19 patients aged 2+ on
06-10 19:30
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
Eikon Therapeutics announced the appointment of Ma. Fatima D. Francisco as an independent director and member of the Compensation Committee, effective June 15, 2026. Francisco, a seasoned leader with over 35 years at Procter & Gamble, where she led major global business units, brings expertise in commercial planning and team development. She also serves on the boards of HP Inc. and Nestlé S.A. Eikon, a biopharmaceutical company focused on innovat...
06-08 12:00
